Video

Dr. Krop on the Role of Neratinib as Extended Adjuvant Therapy in HR+/HER2+ Breast Cancer

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Ian E. Krop, MD, PhD, an associate professor of medicine​, Harvard Medical School​, associate chief, Division of Breast Oncology​, Susan F. Smith Center for Women's Cancers​, medical oncologist and clinical research director​, Breast Oncology Center​, Dana-Farber Cancer Institute, discusses the role of neratinib (Nerlynx) as extended adjuvant therapy in high-risk, hormone receptor (HR)–positive, HER2-positive breast cancer.

​Currently, neratinib is used as extended adjuvant therapy in patients with HR-​positive, HER2-positive breast cancer, says Krop.

 However, ​pertuzumab (Perjeta) has clouded the utility of neratinib​, says Krop. ​Patients enrolled in the ​phase 3 ExteNET study, whichdemonstrated benefit with neratinib ​as extended adjuvant therapy in patients ​with HER2-positive disease, had not received prior pertuzumab​.

Further, adding ado-trastuzumab emtansine (T-DM1; Kadcyla) to the ​armamentarium further complicates treatment selection, Krop explains.

Additionally, as shown in the phase 3 KATHERINE trial, a large proportion of high-risk patients who have multiple ​positive lymph nodesprogress on T-DM1, Krop adds.

As such, in high-risk patients with HR-​positive, HER2-positive disease, neratinib ​should be considered as extended adjuvant therapy. However, this ​treatment decision is more challenging to justify in the lower-risk patient populations, Krop concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity